Novel therapies on the horizon for cutaneous T-cell lymphoma

Speaking from the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland, Rudolf Stadler, MD, PhD, of the University Medical Center Minden, Minden, Germany, discusses new therapy options for cutaneous T-cell lymphoma, including brentuximab vedotin and mogamulizumab. In addition, Prof. Stadler discusses promising targets for therapeutic antibodies.